VBI Vaccines announced interim data from the Phase 2 study evaluating the combination of VBI-2601, BRII-179, VBI’s HBV immunotherapeutic candidate, and BRII-835 an HBV-targeting siRNA candidate, in chronically infected HBV patients. The data, which will be featured in an oral presentation at APASL on February 18, 2023, demonstrated that the combination therapy was generally well-tolerated, restored strong anti-HBsAg antibody responses, and led to improved HBsAg-specific T-cell responses, when compared to BRII-835 alone. Notably, in two participants who received the combination therapy, maximum reductions in HBsAg to an undetectable level or to the lower limit of quantification,LLOQ, were achieved by Week 40, which were associated with robust HBV-specific antibody and T-cell responses.
Published first on TheFly
